Filgrastim Biosimilar Appears Equally Safe, Effective for Breast Cancer

Share this content:
Filgrastim are similar with no clinically meaningful differences in efficacy or safety for the prevention of severe neutropenia.
Filgrastim are similar with no clinically meaningful differences in efficacy or safety for the prevention of severe neutropenia.

Biosimilar filgrastim, EP2006, and the reference filgrastim, Neupogen, are similar with no clinically meaningful differences in efficacy or safety for the prevention of severe neutropenia in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy, a new study published online ahead of print in the journal Annals of Oncology has shown.

For the phase 3 trial, researchers enrolled 218 patients with breast cancer. Participants were randomly assigned to receive 1:1:1:1 non-alternating biosimilar or reference filgrastim or alternating treatments during each cycle of biosimilar or reference filgrastim. Patients received 5 µg/kg/day of filgrastim or its biosimilar over six chemotherapy cycles.

Results demonstrated a duration of severe neutropenia of 1.17±1.11 days with the biosimilar product and 1.20±1.02 days with the reference product.

Researchers found no clinically meaningful differences regarding incidence of febrile neutropenia or infections, hospitalizations due to febrile neutropenia, depth and time of absolute neutrophil count nadir, or time to absolute neutrophil count recovery during all cycles, between the treatment arms.

RELATED: Treatment-Related Side Effects Associated with Physical Activity in Breast Cancer Survivors

In regard to safety, the frequency of adverse events was similar among all four treatment arms.

The findings suggest that biosimilar filgrastim could represent a potential alternative to Neupogen and may ultimately improve access to filgrastim treatment.

In March 2015, the U.S. Food and Drug Administration (FDA) approved Zarxio (filgrastim-sndz), becoming the first FDA-approved biosimilar product.

Reference

  1. Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv281.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters